Drugs Database News Today

Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.

08 Mar, 2024 TauRxs HMTM could become first oral DMT targeting Tau for Alzheimers disease, says GlobalData Share Print...

Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US in October 2024. This significant development signals a forthcoming shift in the drug’s sales trajectory, highlighting Otsuka’s readiness to embrace ...

Popisky – chemie, zkoumání léků, anabolik, lihovin

The top 20 biopharma companies averaged a market capitalisation decline of $3.45 trillion in Q2 to $3.14 trillion in Q3 2022, says GlobalData.

According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.

Pfizer/BioNTech’s Drug Predict to Reach Peak Sales in Two Years by Angela Mohan on  April 16, 2021 at 3:32 PM Tozinameran is forecast to have peak sales of $24.8bn in its second year on the market, which 20% more than Humiras peak sales of $20.5bn, indicating that Comirnaty could be the next top drug in peak sales, as per GlobalData. Quentin Horgan MSc, Analyst for Drugs Database at GlobalData, comments: "Humira has been the top drug by sales for nearly a decade, despite ha...